

ExonHit updates its shareholders on the acquisition of RedPath Integrated Pathology

Paris, France – June 18, 2010 – ExonHit Therapeutics (Alternext: ALEHT) today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG® – Pancreatic cancer, contingent to a complementary assessment of the utility of the product.

Highmark's intention is preliminary and is based mainly upon data from 2006. RedPath has until July 9, 2010 to file a response to support coverage of its product. RedPath is currently putting together documentation that will contain the most recent medical data on the test and which will be supported by KOLs from the sector as well as peer reviewed scientific papers published a few months ago.

If the information filed by RedPath was considered satisfactory, Highmark would continue coverage. If Highmark considered, according to its criteria, that these elements were insufficient, coverage would be discontinued as of September 29, 2010.

ExonHit is currently evaluating the consequences that discontinuation of coverage could have on the acquisition in progress. The extraordinary shareholders' meeting scheduled on June 28, 2010 to decide on the acquisition project may be postponed.

About RedPath Integrated Pathology, Inc.

ExonHit Therapeutics announced on April 26, 2010 the signature of an agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held US molecular diagnostic company, focused on cancer (2009 turnover: USD 5.4 million). According to the terms of this combination agreement, and upon approval of ExonHit's shareholders at an extraordinary shareholders' meeting convened on June 28, 2010, ExonHit will pay an upfront of USD 12.5 million in cash and USD 10 million in stock at the closing of the transaction. Starting in 2012, RedPath's current shareholders may receive subsequent additional payments of up to USD 9.5 million, depending on the achievement of sales targets. The transaction, if approved, is expected to close mid-July 2010.

About the US healthcare system

Medicare is a social insurance program administered by the United States government, providing health insurance coverage to people who are aged 65 and over. *Medicaid* is the United States health program for eligible individuals and families with low incomes and resources. Medicare and Medicaid are administered by the US federal agency called *Centers for Medicare & Medicaid Services* or CMS. Due to the size of the United States, regional reimbursement agencies, such as Highmark, are spread throughout the country.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player active in both therapeutics and diagnostics. The company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with in-house development programs and strategic collaborations, in particular with bioMérieux and Allergan).

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com